Condition:   Cytomegalovirus Infection
Interventions:   Biological: Adoptive Cellular Therapy;   Drug: Best available antiviral drug therapy
Sponsors:   Cell Medica Ltd;   Wellcome Trust;   Choice Pharma Ltd;   Commitum AB;   BioAnaLab
Recruiting - verified February 2010

Condition:   Severe Aortic Valve Stenosis
Intervention:   Device: Medtronic CoreValve System
Sponsor:   Medtronic Bakken Research Center
Recruiting - verified March 2010

Condition:   Hormone Withdrawal Associated Symptoms
Interventions:   Drug: EE20/DRSP (YAZ, BAY86-5300);   Drug: Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)
Sponsor:   Bayer
Not yet recruiting - verified February 2010

Condition:   Colorectal Cancer
Interventions:   Drug: Eicosapentaenoic acid free fatty acid;   Drug: Placebo
Sponsor:   University of Leeds
Not yet recruiting - verified February 2010

Condition:   Head and Neck Cancer
Intervention:   Biological: anti-EGFr Monoclonal Antibody (Zalutumumab) for infusion
Sponsor:   Genmab
Recruiting - verified March 2010

Condition:   Carcinoma, Renal Cell
Interventions:   Drug: BIBF 1120;   Drug: sunitinib
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Conditions:   Influenza A Virus, H1N1 Subtype;   Influenza B Virus;   Influenza, Human;   Influenza, Seasonal
Intervention:   Drug: zanamivir aqueous solution
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Advanced Solid Tumors
Interventions:   Drug: PF-01367338;   Drug: Carboplatin;   Drug: PF-01367338;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: PF-01367338;   Drug: Cisplatin;   Drug: Pemetrexed
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Macular Degeneration
Interventions:   Device: Epimacular Brachytherapy;   Drug: Ranibizumab
Sponsors:   King's College Hospital NHS Trust;   NeoVista
Recruiting - verified February 2010

Condition:   Prostate Cancer
Intervention:   Drug: CNTO888
Sponsor:   Centocor, Inc.
Recruiting - verified February 2010

Condition:   Thyroid Neoplasm
Interventions:   Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
Sponsors:   Bayer;   Onyx Pharmaceuticals
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: protein expression analysis;   Other: diagnostic laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Other: questionnaire administration;   Procedure: cognitive assessment
Sponsor:   Medical Research Council
Recruiting - verified February 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsor:   Cancer Research UK
Recruiting - verified August 2009

Condition:   Endometrial Cancer
Interventions:   Drug: BN83495;   Drug: Megestrol Acetate (MA)
Sponsor:   Ipsen
Recruiting - verified February 2010

Condition:   Fracture Healing
Interventions:   Drug: AMG 785 70mg;   Drug: AMG 785 210mg;   Drug: AMG 785 140 mg;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Drug: Ixabepilone;   Drug: Doxorubicin;   Drug: Paclitaxel
Sponsor:   Bristol-Myers Squibb
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: neratinib;   Other: placebo
Sponsor:   Wyeth
Recruiting - verified March 2010

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified March 2010

Condition:   Hepato Cellular Carcinoma (HCC)
Interventions:   Drug: Brivanib;   Drug: Placebo;   Drug: Sorafenib;   Drug: Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified November 2009

Conditions:   Colorectal Neoplasms;   Neoplasm Metastasis
Interventions:   Drug: aflibercept (AVE0005);   Drug: oxaliplatin;   Drug: 5-FU;   Drug: Folinic Acid
Sponsor:   Sanofi-Aventis
Recruiting - verified March 2010

Condition:   Non-small Cell Lung Cancer (NSCLC)
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: CT-322;   Drug: Bevacizumab;   Drug: Bevacizumab placebo (ie saline solution)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Condition:   Rheumatoid Arthritis
Interventions:   Drug: tocilizumab [RoActemra];   Drug: rituximab [MabThera/Rituxan];   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Non-Hodgkin's Lymphoma
Interventions:   Drug: RO5072759;   Drug: RO5072759;   Drug: CHOP(cyclophosphamide,doxorubicin,vincristine,prednisone);   Drug: FC(fludarabine,cyclophosphamide)
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: tocilizumab [RoActemra];   Drug: methotrexate;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Solid Tumors
Intervention:   Drug: Sunitinib
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Urothelial Cancer
Intervention:   Drug: TKI258
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Condition:   Anemia
Interventions:   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Epilepsies, Partial
Intervention:  
Sponsor:   UCB, Inc.
Recruiting - verified March 2010

Condition:   Melanoma
Interventions:   Biological: OncoVEXGM-CSF;   Biological: GM-CSF
Sponsor:   BioVex Limited
Recruiting - verified March 2010

Condition:   Rheumatoid Arthritis
Intervention:   Drug: Abatacept
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2010

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified October 2009

Condition:   Soft Tissue Sarcoma
Intervention:   Drug: PAZOPANIB
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Acromegaly
Intervention:  
Sponsor:   Ipsen
Recruiting - verified February 2010

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: ofatumumab (GSK1841157) infusion;   Drug: chlorambucil, tablets
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Prostatic Neoplasms
Interventions:   Drug: placebo + docetaxel/prednisone;   Drug: dasatinib + docetaxel/prednisone
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Conditions:   Chemotherapeutic Agent Toxicity;   Lymphoma;   Mucositis;   Neurotoxicity
Interventions:   Drug: glucarpidase;   Drug: leucovorin calcium;   Drug: methotrexate;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Radiation: radiation therapy
Sponsor:   Cancer Research UK
Recruiting - verified November 2008

Condition:   Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions:   Drug: Sunitinib;   Drug: Pazopanib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Hormone Refractory Prostate Cancer;   Bone Metastases
Interventions:   Drug: Alpharadin (Radium-223);   Drug: Placebo
Sponsor:   Algeta ASA
Recruiting - verified March 2009

Condition:   Carcinoma, Hepatocellular
Interventions:   Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified March 2010

Conditions:   Candida;   Candidiasis
Interventions:   Drug: Anidulafungin;   Drug: Fluconazole;   Drug: Voriconazole
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Multiple Sclerosis
Interventions:   Drug: Teriflunomide (HMR1726);   Drug: Placebo
Sponsor:   Sanofi-Aventis
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Drug: bevacizumab [Avastin];   Drug: Standard chemotherapy
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   High Risk Stage III Melanoma
Interventions:   Drug: ipilimumab;   Drug: Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2010

Condition:   Hematologic Neoplasms
Intervention:   Drug: RG7112
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Conditions:   MDS;   Myelodysplastic Syndromes;   Thrombocytopenia
Interventions:   Drug: Placebo;   Biological: Romiplostim
Sponsor:   Amgen
Recruiting - verified March 2010

Conditions:   Transfusional Iron Overload;   Transfusional Hemosiderosis
Interventions:   Drug: Deferasirox;   Drug: Deferoxamine
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified February 2010

Condition:   Venous Thromboembolism
Interventions:   Drug: Xarelto (Rivaroxaban, BAY59-7939);   Drug: Enoxaparin
Sponsors:   Bayer;   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Tumor Antigen-positive Non-Small Cell Lung Cancer
Interventions:   Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic;   Biological: Placebo Control
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Glioma;   Medulloblastoma
Interventions:   Drug: Irinotecan;   Drug: Temozolomide
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions:   Drug: capecitabine;   Other: clinical observation;   Procedure: adjuvant therapy
Sponsor:   Southampton University Hospitals NHS Trust
Recruiting - verified March 2008

Conditions:   Heart Failure;   Anemia;   Cardiovascular Disease;   Ventricular Dysfunction;   Congestive Heart Failure
Interventions:   Drug: Darbepoetin alfa;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Endocrine Tumors
Interventions:   Drug: lanreotide (Autogel formulation);   Other: Placebo
Sponsor:   Ipsen
Recruiting - verified March 2010

Condition:   HIV Infections
Intervention:   Drug: Tipranavir
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Available - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010